Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00701311
Other study ID # 2007-135
Secondary ID
Status Completed
Phase Phase 2
First received June 18, 2008
Last updated September 25, 2014
Start date June 2008
Est. completion date March 2011

Study information

Verified date September 2014
Source William Beaumont Hospitals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Prostatitis is the most common urologic diagnosis in men under the age of 50 and the third most common diagnosis in older men. In Chronic Prostatitis (CP) or Chronic Pelvic Pain Syndrome (CPPS), men have lower urinary tract symptoms, pelvic pain, sexual dysfunction and decreased quality of life. Little is known about the cause of CP/CPPS. Likewise, no definitive therapy exists for CP/CPPS. We plan to study the use of CC-10004 in men with CP/CPPS.


Description:

Prostatitis is the most common urologic diagnosis in men under the age of 50 and the third most common diagnosis in older men. In Chronic Prostatitis (CP) or Chronic Pelvic Pain Syndrome (CPPS), men have lower urinary tract symptoms, pelvic pain, sexual dysfunction and decreased quality of life.

Little is known about the cause of CP/CPPS. Likewise, no definitive therapy exists for CP/CPPS. Unlike bacterial prostatitis, where a clear infecting organism can be determined, CP/CPPS is not always treated with antibiotics.

Due to the significant inflammatory nature of CP/CPPS, most prior therapies have focused on targeting the inflammation. CC-10004 in several studies has shown to be an inhibitor of inflammatory mediators, and may decrease the pain experienced from CP/CPPS.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date March 2011
Est. primary completion date January 2011
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Must be male aged = 18 years at time of consent

- Must understand and voluntarily sign an informed consent form

- Male subjects with at least 3 months of symptoms of CP/CPPS (pain in the pelvic area, penis, scrotum, or perineum) who are refractory to other therapies (e.g. NSAIDS)

- Must be able to adhere to the study visit schedule and other protocol requirements

- Diagnosis of Chronic Prostatitis with a Chronic Prostatitis Symptom Index of at least 15/24

- Must meet the following laboratory criteria:

- Hemoglobin > 9 g/dL

- Hematocrit = 27%

- White blood cell (WBC) count = 3000 /mL (= 3.0 X 109/L) and < 20,000/mL (< 20 X 109/L)

- Platelets = 100,000 /mL (= 100 X 109/L)

- Serum creatinine = 1.5 mg/dL (= 132.6 µmol/L)

- Total bilirubin £ 2.0 mg/dL

- Aspartate transaminase (AST) serum glutamic oxaloacetic transaminase (SGOT), and alanine transaminase (ALT) serum glutamate pyruvic transaminase,(SGPT), < 1.5x upper limit of normal (ULN)

- Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in sexual activity with female capable of becoming pregnant while on study medication and for 28 days after taking the last dose of study medication

Exclusion Criteria:

- Subjects who are female.

- Subjects with a documented positive urine culture within the past three months

- Subjects with duration of symptoms less than three months

- Subjects with genital infections within the past three months

- Subjects with clinical epididymitis within the past three months

- Subjects with known active or prior genitourinary cancers including renal, ureteral, bladder or prostate

- Subjects having received prior radiation to the abdominal or pelvic area

- Subjects with known bladder or ureteral calculi

- Subjects unable to complete a voiding diary

- Subjects with neutropenia (ANC < 750/ mm3)

- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study or confounds the ability to interpret data from the study

- History of active Mycobacterium tuberculosis infection (any subspecies) within 3 years prior to the screening visit. Infections that occurred > 3 years prior to entry must have been effectively treated.

- Positive Tuberculin skin test (Mantoux test)

- Clinically significant abnormality on the chest x-ray (CXR) at screening

- Any clinically significant abnormality on 12-lead ECG at screening

- Use of any investigational medication within 28 days prior to randomization or 5 half-lives if known (whichever is longer)

- History of malignancy within previous 5 years (except for treated basal-cell skin carcinoma(s) and/or fewer than 3 treated squamous-cell skin carcinomas)

- Subjects currently taking chemotherapeutic agents

- Positive human immunodeficiency virus (HIV), hepatitis B, or hepatitis C laboratory test result indicating active infection at screening.

- Subjects with known history of significant disease as determined by the PI

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
CC-10004
CC-10004 20 mg per day

Locations

Country Name City State
United States William Beaumont Hospital Royal Oak Michigan

Sponsors (2)

Lead Sponsor Collaborator
Kenneth Peters, MD Celgene Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Global Response Assessment The primary efficacy measure was a Global Response Assessment (GRA), a subject completed questionnaire that measures improvement in overall symptoms on a 7-point scale: Markedly Improved - 7, Moderately Improved - 6, Mildly Improved - 5, Same - 4, Mildly Worse - 3, Moderately Worse - 2, Markedly Worse - 1.
The primary outcome showing response to treatment was the number of subjects that were moderately or markedly improved on the GRA scale.
12 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02246361 - Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Phase 4
Recruiting NCT00775515 - Laparoscopic Prostatectomy for Chronic Prostatitis Phase 2
Withdrawn NCT03027076 - Microbiome of Urologic Chronic Pelvic Pain Syndrome N/A
Completed NCT00402688 - An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis Phase 3
Suspended NCT00194636 - Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia) Phase 4
Recruiting NCT03720951 - Applying Pulsed Radiofrequency to the Pudendal Nerve Bilaterally Vs Its Application to Sacral Nerve Roots S2,3 and 4 Bilaterally in Chronic Prostatitis N/A
Completed NCT03879486 - Infectious Outcomes of Povidone-iodine Rectal Cleansing Plus Formalin Disinfection of Needle During Prostate Biopsy N/A
Completed NCT01676857 - Chemokine Mechanisms in Chronic Pelvic Pain
Completed NCT00236808 - A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis Phase 3
Completed NCT00169585 - Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA) Phase 3
Completed NCT00277511 - Levofloxacin, Chronic Bacterial Prostatitis Phase 3
Completed NCT01886547 - 2013 Annual National Digital Rectal Exam (DRE) Day Study N/A
Terminated NCT00194597 - Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Phase 4
Completed NCT03931538 - Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study N/A
Completed NCT00675298 - Linkage Analysis in Interstitial Cystitis N/A
Terminated NCT00529386 - Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Phase 1
Completed NCT00103402 - Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome Phase 3
Completed NCT00260637 - Efficacy Study of Acupuncture to Relieve Symptoms of Chronic Prostatitis Phase 2/Phase 3
Recruiting NCT01932645 - Etiology Study of Prostatitis
Completed NCT01826617 - Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome N/A